{"success":true,"data":{"pressRelease":{"id":"168793","rtpr_id":"nGNE90N2pT-20261014","ticker":"NIKI","exchange":"NASDAQ","all_tickers":["NIKI"],"title":"Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002","author":"Globe Newswire","published_at":"2026-10-14T12:00:00.852Z","article_body":"Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply\ncharacterized Alzheimer’s biomarker cohort\n\nPRINCETON, N.J., and NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Niki\nBioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a\nclinical-stage life sciences company focused on unmet medical needs and\ngenomic and biomarker testing solutions, today announced that its wholly owned\nsubsidiary, DiamiR Biosciences Corp. (“DiamiR”), will perform\napolipoprotein E (APOE) genotyping on plasma samples from the Global\nAlzheimer’s Platform Foundation® (“GAP”) Bio-Hermes-002 study cohort.\n\nThe APOE ε4 allele is the strongest known genetic risk factor for late-onset\nAlzheimer’s disease, and APOE genotype informs clinical trial design and\nenrollment as well as risk assessment for amyloid-related imaging\nabnormalities (ARIA) with anti-amyloid therapies. Genotyping directly from\nbanked plasma adds genetic information to existing samples without additional\nblood draws.\n\nBio-Hermes-002 is a GAP-sponsored observational study comparing blood-based\nand digital biomarkers with amyloid PET imaging and cognitive assessments in\ncognitively normal participants, those with mild cognitive impairment, or\nthose with mild Alzheimer’s disease, with an emphasis on recruiting from\nunderrepresented communities. DiamiR will use its New York State-approved,\nplasma-based APOE genotyping assay, and the resulting data will be integrated\nwith the Bio-Hermes dataset and may be available to the research community\nconsistent with GAP’s data-sharing practice.\n\n“We are proud to contribute DiamiR’s plasma-based APOE genotyping to the\nBio-Hermes cohort,” said Alidad Mireskandari, Ph.D., MBA, President and\nChief Operating Officer of Niki BioSolutions. “Determining APOE status from\nplasma unlocks the value of samples already collected, helping researchers\nbetter interpret blood-based biomarkers and design more efficient trials. This\ncollaboration also expands our visibility with the biopharma and diagnostics\ncompanies that rely on Bio-Hermes data.”\n\n“Bio-Hermes was designed to give the field data that will enhance the design\nand execution of Alzheimer's clinical trials,” said John Dwyer, President &\nCEO of the Global Alzheimer’s Platform Foundation. “We are pleased to\ncollaborate with DiamiR. Adding APOE genotype makes Bio-Hermes an even more\nvaluable resource.” \n\nAbout Niki BioSolutions\n\nNiki BioSolutions is a clinical-stage life sciences company focused on unmet\nmedical needs and high-quality genomic and biomarker testing solutions to\nhealthcare providers, research institutions, and life sciences organizations\nthrough its CLIA-certified, CAP-accredited laboratory. The company combines\nproprietary technologies with a commitment to scientific rigor to support\nprecision medicine across a range of therapeutic areas, including\nneurodegeneration and other brain health conditions. Niki BioSolutions\ncollaborates with leading academic centers, disease foundations, and biopharma\ncompanies.\n\nAbout the Global Alzheimer’s Platform Foundation (GAP)\n\nThe Global Alzheimer's Platform Foundation® (GAP) is dedicated to\naccelerating the delivery of treatments, therapies, and cures for people\nliving with neurodegenerative diseases, like Alzheimer's, Parkinson's and\nMultiple Sclerosis. GAP works to lower costs and improve the efficacy of\nclinical trials and is committed to ensuring that no one is left behind. As\npart of its mission, GAP supports more than 75 clinical research sites\nworldwide through study start-up and recruitment activities, promotes\ndiversity in research studies, and champions the citizen scientists who make\nresearch possible.\n\nFor more information, visit www.globalalzplatform.org.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements often use words such as “believe,” “may,” “will,”\n“estimate,” “target,” “continue,” “anticipate,” “intend,”\n“expect,” “should,” “would,” “propose,” “plan,”\n“project,” “forecast,” “predict,” “potential,” “seek,”\n“future,” “outlook,” and similar variations and expressions.\nForward-looking statements are those that do not relate strictly to historical\nor current facts. Examples of forward-looking statements may include, among\nothers, Niki BioSolutions’ ability to successfully operate its business and\nprovide value to stockholders; Niki BioSolutions’ future financial, business\nand operating performance and goals; annualized recurring revenue and customer\nretention; ongoing or future ability to maintain or improve its financial\nposition, cash flows, and liquidity and its expected financial needs;\npotential financing and ability to obtain financing; acquisition strategy and\nproposed acquisitions and, if completed, their potential success and financial\ncontributions; strategy and strategic goals, including being able to\ncapitalize on opportunities; expectations relating to Niki BioSolutions and\nits industry, outlook and market trends; total addressable market and\nserviceable addressable market and related projections; plans, strategies and\nexpectations for increasing revenue and executing growth initiatives. Because\nforward-looking statements relate to the future, they are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Forward-looking\nstatements are not guarantees of future performance, and our actual results of\noperations, financial condition and liquidity and development of the\nindustries in which Niki BioSolutions operates may differ materially from\nthose made in or suggested by the forward-looking statements. Therefore,\ninvestors should not rely on any of these forward-looking statements. Factors\nthat may cause actual results to differ materially include changes in the\nmarkets in which Niki BioSolutions operates, the financial markets, economic,\nbusiness and regulatory factors, and other factors, such as Niki\nBioSolutions’ ability to execute on its strategies. More detailed\ninformation about risk factors can be found in the registration statement on\nForm S-4 filed with the Securities and Exchange Commission (the “SEC”) on\nOctober 6, 2025 (File No. 333-290742), and in other reports filed under the\ncompany’s prior name, Aptorum Group Limited, and that Niki BioSolutions will\nfile with the SEC. Niki BioSolutions does not undertake any duty to update\nforward-looking statements after the date of this press release.\n\nInvestor Contact:\n\nLytham Partners, LLC\nBen Shamsian\n646-829-9701\nshamsian@lythampartners.com\n\nGAP Media Contact:\n\nJulie Sipchen\n773-354-3360\nmedia@globalalzplatform.org\n\n###","article_body_html":"","raw_payload":{"data":{"id":"nGNE90N2pT-20261014","title":"Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002","author":"Globe Newswire","ticker":"NIKI","created":"2026-10-14T12:00:00.852Z","tickers":["NIKI"],"exchange":"NASDAQ","article_body":"Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply\ncharacterized Alzheimer’s biomarker cohort\n\nPRINCETON, N.J., and NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Niki\nBioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a\nclinical-stage life sciences company focused on unmet medical needs and\ngenomic and biomarker testing solutions, today announced that its wholly owned\nsubsidiary, DiamiR Biosciences Corp. (“DiamiR”), will perform\napolipoprotein E (APOE) genotyping on plasma samples from the Global\nAlzheimer’s Platform Foundation® (“GAP”) Bio-Hermes-002 study cohort.\n\nThe APOE ε4 allele is the strongest known genetic risk factor for late-onset\nAlzheimer’s disease, and APOE genotype informs clinical trial design and\nenrollment as well as risk assessment for amyloid-related imaging\nabnormalities (ARIA) with anti-amyloid therapies. Genotyping directly from\nbanked plasma adds genetic information to existing samples without additional\nblood draws.\n\nBio-Hermes-002 is a GAP-sponsored observational study comparing blood-based\nand digital biomarkers with amyloid PET imaging and cognitive assessments in\ncognitively normal participants, those with mild cognitive impairment, or\nthose with mild Alzheimer’s disease, with an emphasis on recruiting from\nunderrepresented communities. DiamiR will use its New York State-approved,\nplasma-based APOE genotyping assay, and the resulting data will be integrated\nwith the Bio-Hermes dataset and may be available to the research community\nconsistent with GAP’s data-sharing practice.\n\n“We are proud to contribute DiamiR’s plasma-based APOE genotyping to the\nBio-Hermes cohort,” said Alidad Mireskandari, Ph.D., MBA, President and\nChief Operating Officer of Niki BioSolutions. “Determining APOE status from\nplasma unlocks the value of samples already collected, helping researchers\nbetter interpret blood-based biomarkers and design more efficient trials. This\ncollaboration also expands our visibility with the biopharma and diagnostics\ncompanies that rely on Bio-Hermes data.”\n\n“Bio-Hermes was designed to give the field data that will enhance the design\nand execution of Alzheimer's clinical trials,” said John Dwyer, President &\nCEO of the Global Alzheimer’s Platform Foundation. “We are pleased to\ncollaborate with DiamiR. Adding APOE genotype makes Bio-Hermes an even more\nvaluable resource.” \n\nAbout Niki BioSolutions\n\nNiki BioSolutions is a clinical-stage life sciences company focused on unmet\nmedical needs and high-quality genomic and biomarker testing solutions to\nhealthcare providers, research institutions, and life sciences organizations\nthrough its CLIA-certified, CAP-accredited laboratory. The company combines\nproprietary technologies with a commitment to scientific rigor to support\nprecision medicine across a range of therapeutic areas, including\nneurodegeneration and other brain health conditions. Niki BioSolutions\ncollaborates with leading academic centers, disease foundations, and biopharma\ncompanies.\n\nAbout the Global Alzheimer’s Platform Foundation (GAP)\n\nThe Global Alzheimer's Platform Foundation® (GAP) is dedicated to\naccelerating the delivery of treatments, therapies, and cures for people\nliving with neurodegenerative diseases, like Alzheimer's, Parkinson's and\nMultiple Sclerosis. GAP works to lower costs and improve the efficacy of\nclinical trials and is committed to ensuring that no one is left behind. As\npart of its mission, GAP supports more than 75 clinical research sites\nworldwide through study start-up and recruitment activities, promotes\ndiversity in research studies, and champions the citizen scientists who make\nresearch possible.\n\nFor more information, visit www.globalalzplatform.org.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements often use words such as “believe,” “may,” “will,”\n“estimate,” “target,” “continue,” “anticipate,” “intend,”\n“expect,” “should,” “would,” “propose,” “plan,”\n“project,” “forecast,” “predict,” “potential,” “seek,”\n“future,” “outlook,” and similar variations and expressions.\nForward-looking statements are those that do not relate strictly to historical\nor current facts. Examples of forward-looking statements may include, among\nothers, Niki BioSolutions’ ability to successfully operate its business and\nprovide value to stockholders; Niki BioSolutions’ future financial, business\nand operating performance and goals; annualized recurring revenue and customer\nretention; ongoing or future ability to maintain or improve its financial\nposition, cash flows, and liquidity and its expected financial needs;\npotential financing and ability to obtain financing; acquisition strategy and\nproposed acquisitions and, if completed, their potential success and financial\ncontributions; strategy and strategic goals, including being able to\ncapitalize on opportunities; expectations relating to Niki BioSolutions and\nits industry, outlook and market trends; total addressable market and\nserviceable addressable market and related projections; plans, strategies and\nexpectations for increasing revenue and executing growth initiatives. Because\nforward-looking statements relate to the future, they are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Forward-looking\nstatements are not guarantees of future performance, and our actual results of\noperations, financial condition and liquidity and development of the\nindustries in which Niki BioSolutions operates may differ materially from\nthose made in or suggested by the forward-looking statements. Therefore,\ninvestors should not rely on any of these forward-looking statements. Factors\nthat may cause actual results to differ materially include changes in the\nmarkets in which Niki BioSolutions operates, the financial markets, economic,\nbusiness and regulatory factors, and other factors, such as Niki\nBioSolutions’ ability to execute on its strategies. More detailed\ninformation about risk factors can be found in the registration statement on\nForm S-4 filed with the Securities and Exchange Commission (the “SEC”) on\nOctober 6, 2025 (File No. 333-290742), and in other reports filed under the\ncompany’s prior name, Aptorum Group Limited, and that Niki BioSolutions will\nfile with the SEC. Niki BioSolutions does not undertake any duty to update\nforward-looking statements after the date of this press release.\n\nInvestor Contact:\n\nLytham Partners, LLC\nBen Shamsian\n646-829-9701\nshamsian@lythampartners.com\n\nGAP Media Contact:\n\nJulie Sipchen\n773-354-3360\nmedia@globalalzplatform.org\n\n###"},"type":"article","timestamp":"2026-10-14T12:00:01.074008404Z","server_sent_at_ms":1791979201074},"received_at":"2026-10-14T12:00:01.124Z","source_url":null},"analysis":{"id":"157043","press_release_id":"168793","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Niki BioSolutions announced its subsidiary DiamiR will perform plasma-based APOE genotyping for the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study cohort.\n\nThe New York State-approved assay adds genetic risk data to banked samples without additional blood draws, and results will be integrated into the Bio-Hermes dataset.\n\nNo financial terms were disclosed; the deal's value is primarily strategic, expanding Niki's visibility with biopharma and diagnostics companies that rely on Bio-Hermes data.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Low-dollar but strategically useful genotyping partnership boosting Niki's Alzheimer's biomarker credentials."},"keyFigures":{"customDimensions":{"gap_research_sites":75}},"quotedText":"This collaboration also expands our visibility with the biopharma and diagnostics companies that rely on Bio-Hermes data.","namedEntities":{"people":[{"name":"Alidad Mireskandari, Ph.D., MBA","role":"President and Chief Operating Officer of Niki BioSolutions"},{"name":"John Dwyer","role":"President & CEO, Global Alzheimer's Platform Foundation"},{"name":"Ben Shamsian","role":"Investor Contact, Lytham Partners"}],"products":["plasma-based APOE genotyping assay","Bio-Hermes-002 study","Bio-Hermes dataset"],"companies":[{"name":"Niki BioSolutions, Inc.","ticker":"NIKI"},{"name":"DiamiR Biosciences Corp.","relationship":"wholly owned subsidiary of Niki BioSolutions"},{"name":"Global Alzheimer's Platform Foundation","relationship":"partner / study sponsor"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A modest commercial/visibility win: DiamiR will provide APOE genotyping for GAP's Bio-Hermes-002 study. No financial terms disclosed and no direct revenue impact stated."},"tickerRelevance":{"others":[],"primary":"NIKI"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap clinical-stage","eventGravity":"non-material research collaboration, no financial terms","sectorWeight":"biotech diagnostics services","issuerAuthored":true}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Niki BioSolutions announced its subsidiary DiamiR will perform plasma-based APOE genotyping for the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study cohort.\n\nThe New York State-approved assay adds genetic risk data to banked samples without additional blood draws, and results will be integrated into the Bio-Hermes dataset.\n\nNo financial terms were disclosed; the deal's value is primarily strategic, expanding Niki's visibility with biopharma and diagnostics companies that rely on Bio-Hermes data.","key_figures":{"customDimensions":{"gap_research_sites":75}},"named_entities":{"people":[{"name":"Alidad Mireskandari, Ph.D., MBA","role":"President and Chief Operating Officer of Niki BioSolutions"},{"name":"John Dwyer","role":"President & CEO, Global Alzheimer's Platform Foundation"},{"name":"Ben Shamsian","role":"Investor Contact, Lytham Partners"}],"products":["plasma-based APOE genotyping assay","Bio-Hermes-002 study","Bio-Hermes dataset"],"companies":[{"name":"Niki BioSolutions, Inc.","ticker":"NIKI"},{"name":"DiamiR Biosciences Corp.","relationship":"wholly owned subsidiary of Niki BioSolutions"},{"name":"Global Alzheimer's Platform Foundation","relationship":"partner / study sponsor"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:00:10.674Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap clinical-stage","eventGravity":"non-material research collaboration, no financial terms","sectorWeight":"biotech diagnostics services","issuerAuthored":true}},"durationMs":4972,"modelName":"glm-5.3-flashx"}}